Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:12/6/2018
Start Date:April 23, 2008
End Date:September 28, 2017

Use our guide to learn which trials are right for you!

Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle
(Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib
hydrochloride work in treating patients with metastatic breast cancer. Drugs used in
chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, can prevent cancer growth by
blocking the ability of cancer cells to grow and spread. Erlotinib hydrochloride may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial
evaluates a maintenance treatment with erlotinib and bevacizumab after Nab-paclitaxel and
bevacizumab which may control cancer growth with biologic therapies.

PRIMARY OBJECTIVES:

I. Progression free survival.

SECONDARY OBJECTIVES:

I. Response rate.

II. Overall survival.

III. Safety and toxicity.

IV. Exploratory biomarkers will be assessed as potential predictors of response to treatment
including: expression of epidermal growth factor receptor (EGFR) and secreted protein acidic
and rich in cysteine (SPARC) in the primary tumor and changes in levels of circulating tumor
cells (CTCs) and circulating endothelial cells (CECs).

OUTLINE:

INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation
intravenously (IV) on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and
15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or
unacceptable toxicity.

MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable
disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes
once every 14 or 21 days and erlotinib hydrochloride orally (PO) once daily (QD) in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up per physician discretion.

Inclusion Criteria:

- Have histologically confirmed invasive breast cancer that is estrogen receptor (ER)
negative (=< 10%), progesterone receptor (PR) negative (=< 10%) and human epidermal
growth factor receptor 2 (HER2) normal (=< 10% of cells) by immunohistochemistry (IHC)
or fluorescence in situ hybridization (FISH)

- Be receiving first-line therapy for metastatic disease

- Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria;
X-rays, scans or physical examinations used for tumor measurement must have been
completed within 28 days prior to registration; X-rays, scans or other tests for
assessment of non-measurable disease must have been performed within 42 days prior to
registration

- OR non-measurable disease only, with rising serum cancer antigen (CA)15-3 or CA 27.29
or carcinoembryonic antigen (CEA) documented by two consecutive measurements taken at
least 14 days apart with the most recent measurement being within 42 days prior to
registration; the second CA 15-3 or CA 27.29 or CEA value must have at least a 20%
increase over the first and for CA 15-3 or CA 27.29 be greater than or equal to 40
units/mL or for CEA be greater than or equal to 4 ng/mL

- Subjects with brain metastases as their first site of disease recurrence may be
eligible if treated by definitive radiation (stereotactic radiosurgery or whole brain)
with clinically controlled neurologic symptoms for a period of 21 days prior to study
treatment

- Bilirubin =< 1.5 mg/dL

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper
limit of normal, unless bone metastasis is present in the absence of liver metastasis

- Alkaline phosphatase =< 2.5 X upper limit of normal, unless bone metastasis is present
in the absence of liver metastasis

- Platelets > 100,000 cells/mm^3

- Hemoglobin > 9.0 g/dL

- Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

- Creatinine =< 1.5 mg/dL is recommended; however, institutional norms are acceptable

- If of childbearing potential must have a negative pregnancy test and use an effective
method to avoid pregnancy for the duration of the trial and for at least 6 months
after completion of study therapy

- Pre-existing peripheral neuropathy, if present, must be < grade 2 (per Common
Terminology Criteria for Adverse Events [CTCAE] version 3.0)

- Patients must be informed of the investigational nature of this study and must sign
and give informed consent in accordance with institutional standards and federal
guidelines

Exclusion Criteria:

- Recurrent disease within 12 months after completion of adjuvant chemotherapy
containing a weekly taxane

- Central nervous system (CNS) metastases that are symptomatic and/or requiring steroids

- Pre-existing nephritic syndrome

- Serious intercurrent medical or psychiatric illness including serious active infection

- Inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or
diastolic blood pressure > 100 mmHg on antihypertensive medications)

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study
enrollment

- History of stroke or transient ischemic attack within 6 months prior to study
enrollment

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study enrollment or anticipation of need for major surgical procedure during
the course of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
within 6 months prior to study enrollment

- Serious, non-healing wound, ulcer, or bone fracture

- Proteinuria at screening as demonstrated by either:

- Urine protein:creatinine (UPC) ratio >= 1.0 at screening OR

- Urine dipstick for proteinuria > 2+ (patients discovered to have > 2+ proteinuria
on dipstick urinalysis at baseline must have a UPC ratio done that is < 1.0 to be
eligible; if the UPC ratio is >= 1.0 then the patient should undergo a 24-hour
urine collection which must demonstrate =< 1 g of protein in 24 hours for the
patient to be eligible)

- Known hypersensitivity to any component of bevacizumab or to nab-paclitaxel
(paclitaxel albumin-stabilized nanoparticle formulation)
We found this trial at
17
sites
1100 Fairview Avenue North
Seattle, Washington 98109
206-667-4584
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium The Fred Hutchinson/University of Washington Cancer...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
820 North Chelan Avenue
Wenatchee, Washington 98801
509) 663-8711
Wenatchee Valley Medical Center Established on July 21, 2013, Confluence Health is an affiliation between...
?
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Bend, Oregon 97701
?
mi
from
Bend, OR
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
310 Sunnyview Ln
Kalispell, Montana 59901
(406) 752-5111
Kalispell Regional Medical Center Nestled in the beautiful Flathead Valley of Northwestern Montana, Kalispell Regional...
?
mi
from
Kalispell, MT
Click here to add this to my saved trials
Kennewick, Washington 99336
?
mi
from
Kennewick, WA
Click here to add this to my saved trials
Kirkland, Washington 98034
?
mi
from
Kirkland, WA
Click here to add this to my saved trials
Lewiston, Idaho 83501
?
mi
from
Lewiston, ID
Click here to add this to my saved trials
?
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Redmond, Washington 98052
?
mi
from
Redmond, WA
Click here to add this to my saved trials
Sequim, Washington 98384
?
mi
from
Sequim, WA
Click here to add this to my saved trials
Spokane, Washington 99208
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Tacoma, Washington 98405
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Yuma, Arizona 85364
?
mi
from
Yuma, AZ
Click here to add this to my saved trials